These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34348578)

  • 1. Resolution of Harada disease-like uveitis after quadrivalent human papillomavirus vaccination: a case report.
    Kong K; Ding X; Ni Y
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-4. PubMed ID: 34348578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Report: Posterior Uveitis after Divalent Human Papillomavirus Vaccination in an Asian Female.
    Ye H; Feng H; Zhao P; Fei P
    Optom Vis Sci; 2020 Jun; 97(6):390-394. PubMed ID: 32511159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events.
    Geier DA; Geier MR
    Clin Rheumatol; 2015 Jul; 34(7):1225-31. PubMed ID: 25535199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
    Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panuveitis With Exudative Retinal Detachments After Vaccination Against Human Papilloma Virus.
    Dansingani KK; Suzuki M; Naysan J; Samson CM; Spaide RF; Fisher YL
    Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):967-70. PubMed ID: 26469238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects.
    Grimaldi-Bensouda L; Guillemot D; Godeau B; Bénichou J; Lebrun-Frenay C; Papeix C; Labauge P; Berquin P; Penfornis A; Benhamou PY; Nicolino M; Simon A; Viallard JF; Costedoat-Chalumeau N; Courcoux MF; Pondarré C; Hilliquin P; Chatelus E; Foltz V; Guillaume S; Rossignol M; Abenhaim L;
    J Intern Med; 2014 Apr; 275(4):398-408. PubMed ID: 24206418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term study of a quadrivalent human papillomavirus vaccine.
    Ferris D; Samakoses R; Block SL; Lazcano-Ponce E; Restrepo JA; Reisinger KS; Mehlsen J; Chatterjee A; Iversen OE; Sings HL; Shou Q; Sausser TA; Saah A
    Pediatrics; 2014 Sep; 134(3):e657-65. PubMed ID: 25136050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):630-2. PubMed ID: 20508594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database.
    Geier DA; Geier MR
    Immunol Res; 2017 Feb; 65(1):46-54. PubMed ID: 27406735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study.
    Liu EY; Smith LM; Ellis AK; Whitaker H; Law B; Kwong JC; Farrington P; Lévesque LE
    CMAJ; 2018 May; 190(21):E648-E655. PubMed ID: 29807937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Chesson HW; Curtis CR; Gee J; Bocchini JA; Unger ER;
    MMWR Recomm Rep; 2014 Aug; 63(RR-05):1-30. PubMed ID: 25167164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico.
    Ortiz AP; Ortiz-Ortiz KJ; Ríos M; Laborde J; Kulkarni A; Pillsbury M; Lauschke A; Monsanto HA; Marques-Goyco C
    PLoS One; 2017; 12(11):e0184540. PubMed ID: 29190725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quadrivalent HPV vaccination reactions--more hype than harm.
    Douglas RJ
    Aust Fam Physician; 2009 Mar; 38(3):139-42. PubMed ID: 19283255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Dec; 60(50):1705-8. PubMed ID: 22189893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States.
    Stokley S; Jeyarajah J; Yankey D; Cano M; Gee J; Roark J; Curtis RC; Markowitz L; ;
    MMWR Morb Mortal Wkly Rep; 2014 Jul; 63(29):620-4. PubMed ID: 25055185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013.
    Moro PL; Zheteyeva Y; Lewis P; Shi J; Yue X; Museru OI; Broder K
    Vaccine; 2015 Jan; 33(4):519-22. PubMed ID: 25500173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
    Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
    Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic lupus erythematosus following human papillomavirus vaccination: A case-based review.
    He N; Leng X; Zeng X
    Int J Rheum Dis; 2022 Oct; 25(10):1208-1212. PubMed ID: 35948863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 Jul; 62(29):591-5. PubMed ID: 23884346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.